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were almost identical; only 2 nt differ-
ences were found. No epidemiologic 
or geographic link connected these 2 
patients. The only link was the date of 
sample collection. Both patients were 
ill during the summer, which sug-
gests possible consumption of under-
cooked, or raw, contaminated food as 
the source of infection. The sequences 
from these 2 patients were most closely 
related to the sequences from patients 
involved in the outbreaks in France 
(Figure). These sequences all form a 
group with the HEV4 virus identified 
in the pig in Belgium in 2008, thereby 
suggesting a zoonotic origin.
Because Statens Serum Institut is 
the only laboratory in Denmark that 
offers diagnostic testing for HEV, we 
consider our national surveillance to 
be fairly complete. Prospective sur-
veillance will show whether HEV4 
becomes established within Denmark. 
To date, HEV4 has not been detected 
in animal populations in Denmark. In 
China, similarity of HEV4 data be-
tween strains from humans and other 
animals in the same geographic areas 
was high, which is highly suggestive 
of zoonotic transmission (3). Be-
cause of the rare detection of HEV4 
in Europe, these types of data are not 
yet available for European countries. 
However, the close phylogenetic re-
lationship between the strains from 
humans in Denmark and France and 
the strain from the pig in Belgium 
suggests a zoonotic origin for this 
genotype in these countries. This sug-
gestion is further supported by the fact 
that some of the strains from France 
were associated with the consumption 
of pork liver sausage. 
The emergence of autochtho-
nous HEV4 infection in human 
populations in 4 European countries, 
and its detection in different years 
(2006/2007, 2008, 2009, 2011, and 
2012), suggests that this genotype 
may be established in Europe. Thus, 
for the purpose of ensuring HEV4 
detection, diagnostic and genotyping 
methods should be evaluated.
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Tour Leaders’ 
Knowledge of and 
Attitudes toward 
Rabies Vaccination, 
Taiwan
To the Editor: Tour leaders ac-
company and care for the health, com-
fort, and safety of travelers in group 
tours, which remain a popular method 
of international travel in Asian coun-
tries, including Taiwan (1). In addi-
tion to travel agents and physicians, 
tour leaders can also play a key role 
in the prevention and management of 
travel-related infectious diseases dur-
ing group tours.
Rabies is a viral, vaccine-prevent-
able, zoonotic, infectious disease that 
occurs throughout the world; it is al-
most always fatal (2, 3). According to 
records of postexposure prophylaxis, 
≈0.4% of all travelers have experi-
enced 1 animal (at-risk) bite per month 
of stay in a rabies-endemic country; in 
the past 10 years, at least 22 confirmed 
cases of rabies among travelers have 
been reported (4,5). Given that ra-
bies-endemic countries include many 
popular tourist destinations, rabies 
has become one of the most serious 
travel-related infectious diseases (3). 
In 2011, nearly half of the 9 million 
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travelers from Taiwan participated in 
group tours to Southeast Asia, a highly 
rabies-endemic area. Thus, tour lead-
ers might be in a position to influence 
rabies risk among group travelers to 
high-risk destinations.
To determine tour leaders’ knowl-
edge of and attitudes toward rabies 
vaccination, we conducted a cross-
sectional survey among those work-
ing in international tourism in Taiwan. 
A self-administered questionnaire was 
given to 191 tour leaders who attended 
6 seminars in Taiwan during May–Oc-
tober 2010. This questionnaire (online 
Technical Appendix, wwwnc.cdc.gov/
EID/article/20/1/13-0673-Techapp1.
pdf) comprised 3 sections: demo-
graphic information; attitude toward 
rabies vaccination; and knowledge 
about general rabies-related informa-
tion, prevention, and postexposure 
management. The questionnaire was 
based on a literature review. Statisti-
cal analysis was performed by using 
SPSS for Windows 11.0 (SPSS, Chi-
cago, IL, USA) and χ2 test and step-
wise logistic regression analysis; p 
value was set at 0.05.
A total of 175 (91.6%) tour lead-
ers completed the questionnaire. Re-
spondent mean age (± SD) was 44.5 
± 11.8 (range 20–71) years. Among 
them, 58.3% were women, and 82.3% 
had a college degree or above. A 
positive attitude toward preexposure 
rabies vaccination was reported by 
>90% of tour leaders (Table). Tour 
leaders who intended to receive vac-
cination showed higher willingness to 
recommend vaccination to group trav-
elers. Most (46.3%) tour leaders indi-
cated that the main factor influencing 
their intention to receive vaccination 
was disease severity. However, the 
mean percentage of accurate respons-
es to rabies-related questions was only 
52.4% (Table). Most (49.1%) tour 
leaders incorrectly thought that it often 
takes 1 day to 1 week for symptoms 
of rabies to develop after a person is 
infected. Only 44.6% of respondents 
knew that the mortality rate for rabies 
is >99% after symptoms appear. Re-
garding the question “Where is rabies 
present?” the most often chosen incor-
rect answer was Southeast Asia and 
mainland China only (32.0%). A posi-
tive attitude toward rabies vaccination 
and poor knowledge were noted re-
gardless of tour leader age and educa-
tion level. Multiple logistic regression 
analyses showed that the response to 
the question about mortality rate was a 
significant predicting variable regard-
ing tour leaders’ attitudes toward vac-
cination. Tour leaders who understood 
the high mortality rate associated with 
rabies tended to receive preexposure 
rabies vaccination (odds ratio 5.578, 
95% CI 1.190–26.170, p = 0.029) 
and would recommend vaccination 
to group travelers (odds ratio 15.931, 
95% CI 1.840–138.090, p = 0.012).
Our study revealed that tour 
leaders in Taiwan had a positive at-
titude toward rabies vaccination but 
a relatively low level of knowledge 
about rabies. Knowledge was poor 
regarding clinical manifestations, 
rabies-endemic areas, prevention, 
and management. We believe that the 
poor knowledge reflects insufficient 
information or education about rabies 
provided to the public or to tour lead-
ers in Taiwan, which is a rabies-free 
area. Previous studies revealed that 
most animal-bitten travelers did not 
receive postexposure prophylaxis con-
sistent with World Health Organiza-
tion guidelines (4,6), possibly because 
travelers and local health practitioners 
were unfamiliar with the disease (7,8). 
Therefore, tour leaders with adequate 
knowledge about rabies might be able 
to provide immediate information to 
exposed travelers.
Knowledge of the high mortal-
ity rate associated with rabies was an 
independent factor influencing tour 
leaders’ attitudes toward preexposure 
rabies vaccination. This finding was 
consistent with previous study find-
ings that low preexposure vaccina-
tion rates among travelers might result 
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Table. Respondent’s attitude and knowledge of rabies and vaccination (n = 175), Taiwan, 2010* 
Survey	section,	questions 
Response,	% 
Yes No No	idea 
Correct	
answer 
Incorrect 
answer 
Don’t 
know 
Section	II:	attitude	toward	rabies	vaccination       
 1.	Do you	intend	to	receive	rabies vaccination	before	visiting	
     a rabies-endemic	area? 
92.6 3.4 4.0 NA NA NA 
 2.	Will	you	recommend	rabies	vaccination	to	travelers	before	
     they	visit	a	rabies-endemic	area? 
94.3 1.7 4.0 NA NA NA 
Section	III:	knowledge	about	rabies       
 1.	Transmission	mode NA NA NA 97.1 1.7 1.1 
 2.	Infectious	agent NA NA NA 77.7 16.0 6.3 
 3.	Particular	symptom NA NA NA 51.4 37.7 10.9 
 4.	Incubation	period NA NA NA 25.1 65.8 9.1 
 5.	Mortality	rate NA NA NA 44.6 34.3 21.1 
 6.	Rabies-endemic	area NA NA NA 38.3 45.1 16.6 
 7.	Preexposure	vaccination	protocol NA NA NA 21.7 52.1 26.2 
 8.	Postexposure	vaccination	protocol NA NA NA 41.7 69.7 28.0 
 9.	Postexposure	management NA NA NA 73.7 14.3 12.0 
*NA,	not	applicable. 
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from the lack of knowledge among the 
travelers themselves or among their 
pretravel health care providers (5,9). 
In recent years, the World Health 
Organization and the GeoSentinel 
Surveillance Network recommended 
that persons planning to visit rabies-
endemic areas receive preexposure 
prophylaxis before traveling (6,10). 
Understanding the factors influenc-
ing acceptance of vaccination could 
help governments develop and insti-
tute strategies for disease prevention. 
Thus, the Taiwan government should 
enhance tour leaders’ knowledge 
about rabies, especially regarding the 
high mortality rate. Education of tour 
leaders could, in turn, increase vacci-
nation rates and help with prevention 
and management of rabies.
The results of this study are rel-
evant for countries other than Taiwan 
because many Asian tourists partici-
pate in group tours. We suggest that 
governments place more emphasis 
on tour leaders’ education concerning 
travel medicine. Such education could 
not only improve the quality of group 
tours but also help prevent travel- 
related infectious diseases.
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Corynebacterium 
ulcerans in Ferrets
To the Editor: Infection with Co-
rynebacterium ulcerans occurs spo-
radically throughout the world, and in 
the United Kingdom it has emerged as 
the most common cause of diphtheria-
like disease (1). C. ulcerans, along 
with C. diphtheriae and C. pseudo-
tuberculosis, can be lysogenized by 
diphtheria toxin–encoding bacterio-
phages; this process enables the or-
ganism to induce its characteristic 
sequela (the diphtheritic membrane) 
in the host. C. ulcerans in the envi-
ronment has been a source of mastitis 
in cattle and a cause of diphtheria in 
humans who consume unpasteurized, 
contaminated milk. The organism has 
been isolated from various domes-
tic, wild, and laboratory animals; ad-
ditional definitive sources are dogs, 
cats, and pigs (2). C. ulcerans has 
been isolated from bonnet macaques 
with mastitis and from the cephalic 
implants of purpose-bred macaques 
used in cognitive neuroscience experi-
ments (3,4). We report isolation of C. 
ulcerans from cephalic implants in 4 
ferrets (Mustela putorius furo) and the 
oropharynx of 1 ferret, all used in im-
aging experiments in Massachusetts, 
USA, during 2007–2008.
All ferrets described here were 
purpose-bred, domestic ferrets, pur-
chased from a commercial vendor. 
The index case occurred in a ferret 
with a cephalic implant. Microbio-
logical culture of a purulent discharge 
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